|
CYCC | Cyclacel Pharmaceuticals, Inc. |
|
|
CYCC | Cyclacel Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.06 |
| Leverage | 17.50% |
| Market Cap | $ 65.3m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -6.4m |
| Margin | -13642.44% |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey.